NEXTCURE, INC.

Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting a immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).